May 31, 2011 · After reviewing the results and discussing the appropriateness of labeling a drug for blacks only, the Cardiovascular and Renal Drugs Advisory Committee voted unanimously in favor of approving BiDil, making it the first drug ever approved for treatment in a single race. 23

Nov 11, 2004 · We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable...

Jun 12, 2024 · BiDil is used to treat heart failure. Learn about side effects, interactions and indications.

Hydralazine/isosorbide dinitrate, sold under the brand name Bidil, is a fixed-dose combination medication used to treat self-identified Black people with congestive heart failure. [1]

Feb 1, 2025 · Isosorbide dinitrate and hydralazine combination is used to treat heart failure in black patients. Isosorbide dinitrate belongs to the group of medicines called nitrates. It works by relaxing the blood vessels and increasing the supply of blood and oxygen to the heart while reducing its work load.

BiDil tablets contain Isosorbide dinitrate and Hydralazine. Both the drugs act as direct vasodilators and are used in patients with heart failure. Isosorbide dinitrate and hydralazine Uses: Heart failure with reduced ejection fraction (HFrEF):

mortality in the BiDil-194 treated group (p=0.012; see Table 1 and Figure 1). The primary endpoint was also 195 statistically in favor of BiDil (p £ 0.021). The BiDil-treated group also showed a 39% 196 reduction in the risk of a first hospitalization for heart failure (p<0.001; see Table 1 and 197 Figure 2) and had statistically significant ...

Jul 19, 2022 · BiDil is a fixed-dose combination of isosorbide dinitrate, a vasodilator with effects on both arteries and veins, and hydralazine hydrochloride, a predominantly arterial vasodilator.

BiDil is a prescription medicine that is approved for use with other heart medicines to treat heart failure in black patients to improve survival, improve heart failure symptoms, and help patients stay out of the hospital longer.

BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status.